Juliana Chan. Show Affiliations »
Abstract
Mesh： See more » AdultAge DistributionAnti-HIV Agents/therapeutic useCommunicable Disease Control/organization & administrationDisease ManagementFemaleHepatitis C/diagnosisHepatitis C/drug therapyHepatitis C/epidemiologyHepatitis C/transmissionHepatitis C, Chronic/diagnosisHepatitis C, Chronic/drug therapyHepatitis C, Chronic/epidemiologyHepatitis C, Chronic/transmissionHeterocyclic Compounds, 3-Ring/adverse effectsHeterocyclic Compounds, 3-Ring/therapeutic useHumansIncidenceLiver Cirrhosis/prevention & controlLiver Cirrhosis/virologyMaleMiddle AgedNeeds AssessmentPrisoners/statistics & numerical dataPrisonsRibavirin/adverse effectsRibavirin/therapeutic useRisk AssessmentSex DistributionSimeprevirSofosbuvirSulfonamides/adverse effectsSulfonamides/therapeutic useTelemedicine/statistics & numerical dataTreatment OutcomeUnited StatesUridine Monophosphate/adverse effectsUridine Monophosphate/analogs & derivativesUridine Monophosphate/therapeutic useYoung Adult
Substances： See more » Anti-HIV AgentsHeterocyclic Compounds, 3-RingSulfonamidesRibavirinSimeprevirUridine MonophosphateSofosbuvir
Year: 2014 PMID： 24863270 DOI： 10.1016/j.disamonth.2014.04.002
Source DB: PubMed Journal: Dis Mon ISSN： 0011-5029 Impact factor: 3.800